Start Date
March 31, 2022
Primary Completion Date
March 31, 2026
Study Completion Date
December 31, 2026
131I-Omburtamab
Omburtamab is a murine IgG1 monoclonal antibody, recognizing CD276 (also known as B7-H3).
Convention Enhanced Delivery
The planned intervention includes surgical placement of a small caliber cannula into the tumor located in the pons using standard stereotactic techniques followed by CED of 131Iomburtamb.
Lead Sponsor
Collaborators (1)
Labcorp Corporation of America Holdings, Inc
INDUSTRY
Invicro
OTHER
Y-mAbs Therapeutics
INDUSTRY